From StructContinue beyond “Insulet’s Abbott connection comes with two hatsBack to the brief ↗Feed / PODD

Insulet Corporation

PODD

Healthcare · 151.46 +2.3% today

You’ve read what changed. Here’s whether the market is confirming it.

Isolated · not yet confirmedMarket checked 19 Aug, 15:55 GMT-4

Jodie situation report

Insulet Corporation's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.

Customer1
Supplier1
Partner2
Company+2.3% todayVolume comparison unavailable
Market group0 of 7 activeUnrelated Stocks · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Monitor the reported 45.2% revenue increase excluding 14.2% FX and its attribution to higher volumes from a growing customer base and higher Omnipod 5 ASP vs Omnipod DASH.
  • Monitor higher interest expense tied to issued 6.5% senior notes and renewed swaps and the company’s ~ $40M net interest expense expectation for 2026.

Invalidation: The isolated read changes if PODD's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind PODD

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AMGN21.0% of PODDcustomerMay 6, 2026

21 Table of Contents Drug Delivery Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

ABTAbbott LaboratoriessupplierNov 6, 2025

Further, we integrated Omnipod 5 with Dexcom’s G7 CGM sensor in Germany, Sweden, Denmark, Finland and Italy, and with Abbott’s FreeStyle Libre 2 Plus sensor in Australia.

Depended on by

TNDMTandem Diabetes Care, Inc.competitorMay 7, 2026

We compete in markets worldwide with companies that manufacture insulin delivery devices, primarily Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed) and Sequel.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

PODD is currently a Follower in the organic co-movement group Unrelated Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for PODD; it is not active in the latest market snapshot.